Skip to main content Accessibility help
×
Home

Tardive dyskinesia: motor system impairments, cognition and everyday functioning

  • Martin Strassnig (a1), Amie Rosenfeld (a1) and Philip D. Harvey (a2)

Abstract

The recent approval of treatments for tardive dyskinesia (TD) has rekindled interest in this chronic and previously recalcitrant condition. A large proportion of patients with chronic mental illness suffer from various degrees of TD. Even the newer antipsychotics constitute a liability for TD, and their liberal prescription might lead to emergence of new TD in patient populations previously less exposed to antipsychotics, such as those with depression, bipolar disorder, autism, or even attention deficit hyperactivity disorder. The association of TD with activity limitations remains poorly understood. We review potential new avenues of assessing the functional sequelae of TD, such as the performance of instrumental activities of daily living, residential status, and employment outcomes. We identify several mediating aspects, including physical performance measures and cognition, that may represent links between TD and everyday performance, as well as potential treatment targets.

Copyright

Corresponding author

*Address correspondence to: Martin Strassnig, Department of Integrated Medical Science, Florida Atlantic University, Charles Schmidt College of Medicine, 777 Glades Road, Boca Raton, Florida 33431. (Email: mstrassnig@health.fau.edu)

References

Hide All
1. Haro, JM, Salvador-Carulla, L. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia. CNS Drugs. 2006; 20(4): 293301.
2. Lerner, V, Miodownik, C. Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? a modern treatment. Curr Psychiatry Rep. 2011; 13(4): 295304.
3. Merrill, RM, Lyon, JL, Matiaco, PM. Tardive and spontaneous dyskinesia incidence in the general population. BMC Psychiatry. 2013; 13: 152. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681708/. Accessed August 11, 2019.
4. Carbon, M, Hsieh, CH, Kane, JM, Correll, CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017; 78(3): e264e278.
5. Correll, CU, Schenk, EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008; 21(2): 151156.
6. Woods, SW, Morgenstern, H, Saksa, JR, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry. 2010; 71(4): 463474.
7. Kane, JM, Smith, JM. Tardive dyskinesia: prevalence and risk factors, 1959 to1979. Arch Gen Psychiatry. 1982; 39(4): 473481.
8. Ganguli, R, Strassnig, M. Are older antipsychotic drugs obsolete? BMJ. 2006; 332(7554): 13461347.
9. Crystal, S, Olfson, M, Huang, C, Pincus, H, Gerhard, T. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Aff (Millwood). 2009; 28(5): w770w781.
10. Monasterio, E, McKean, A. Quetiapine use: science or clever marketing? Aust N Z J Psychiatry. 2013; 47(1): 9697.
11. Owens, DCG. A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs. Cambridge: Cambridge University Press; 1999.
12. Casey, DE. Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry. 2000; 61(Suppl 4): 59.
13. Souza, R, Remington, G, Chowdhury, NI, et al. Association study of the GSK-3B gene with tardive dyskinesia in European Caucasians. Eur Neuropsychopharmacol. 2009; 20(10): 688694.
14. Lerner, PP, Miodownik, C, Lerner, V. Tardive dyskinesia (syndrome): current concept and modern approaches to its management. Psychiatry Clin Neurosci. 2015; 69(6): 321334.
15. Bhidayasiri, R, Fahn, S, Weiner, WJ, et al. Evidence-based guideline: treatment of tardive syndromes. Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013; 81(5): 463469.
16. Aia, PG, Revuelta, GJ, Cloud, LJ, Factor, SA. Tardive dyskinesia. Curr Treat Options Neurol. 2011; 13(3): 231241.
17. Lieberman, JA, Saltz, BL, Johns, CA, Pollack, S, Borenstein, M, Kane, J. The effect of clozapine on tardive dyskinesia. Br J Psychiatry. 1999; 158: 503510.
18. Welter, ML, Grabli, D, Vidailhet, M. Deep brain stimulation for hyperkinetics disorders; dystonia, tardive dyskinesia, and tics. Curr Opin Neurol. 2010; 23(4): 420425.
19. Kaur, N, Kumar, P, Jamwal, S, Deshmukh, R, Gauttam, V. Tetrabenazine: spotlight on drug review. Ann Neurosci. 2016; 23(3): 176185.
20. Wimalasena, K. Vesicular monoamine transporters: structure–function, pharmacology, and medicinal chemistry. Med Res Rev. 2011; 31(4): 483519.
21. Voelker, R. Tardive dyskinesia drug approved. JAMA. 2017; 317(19): 1942.
22. Citrome, L. Valbenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication. What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2017; 71(7): doi: 10.1111/ijcp.12964. Epub ahead of print May 12.
23. Yassa, R, Jones, BD. Complications of tardive dyskinesia: a review. Psychosomatics. 1985; 26(4): 305313.
24. Lohr, JB, Caliguri, MP. Quantitative instrumental measurement of tardive dyskinesia: a review. Neuropsychopharmacology.. 1993; 6(4): 231239.
25. Kuo, SH, Jankovic, J. Tardive gait. Clin Neurol Neurosurg. 2008; 110(2): 198201.
26. Simpson, GM, Shrivastava, RK. Abnormal gaits in tardive dyskinesia. Am J Psychiatry. 1978; 135(7): 865.
27. Yassa, R. Functional impairment in tardive dyskinesia: medical and psychosocial dimensions. Acta Psychiatr Scand. 1989; 80(1): 6467.
28. Lauterbach, EC, Singh, H, Simpson, GM, Morrison, RL. Gait disorders in tardive dyskinesia. Acta Psychiatr Scand. 1990; 82(3): 267.
29. Montero-Odasso, M, Verghese, J, Beauchet, O, Hausdorff, JM. Gait and cognition: a complementary approach to understanding brain function and the risk of falling. J Am Geriatr Soc. 2012; 60(11): 21272136.
30. Van Emmerik, RE, Sprague, RL, Newell, KM. Quantification of postural sway patterns in tardive dyskinesia. Mov Disord. 1993; 8(3): 305314.
31. Ko, YG, Van Emmerik, RE, Sprague, RL, Newell, KM. Postural stability, tardive dyskinesia and developmental disability. J Intellect Disabil Res. 1992; 36(Pt 4): 309323.
32. Leavy, B, Byberg, L, Michaëlsson, K, Melhus, H, Åberg, AC. The fall descriptions and health characteristics of older adults with hip fracture: a mixed methods study. BMC Geriatr. 2015; 15: 40. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428087/. Accessed August 11, 2017.
33. Liu-Ambrose, T, Khan, KM, Donaldson, MG, Eng, JJ, Lord, SR, McKay, HA. Falls-related self-efficacy is independently associated with balance and mobility in older women with low bone mass. J Gerontol A Biol Sci Med Sci. 2006; 61(8): 832838.
34. Blanchet, PJ, Rompre, PH, Lavinge, GJ, Lamarche, C. Oral dyskinesia: a clinical overview. Int J Prosthodont. 2005; 18(1): 1019.
35. Achiron, A, Melamed, E. Tardive eating dystonia. Mov Disord. 1990; 5(4): 331333.
36. Girard, P, Monette, C, Normandeau, L, et al. Contribution of orodental status to the intensity of orofacial tardive dyskinesia: an interdisciplinary and video-based assessment. J Psychiatr Res. 2012; 46(5): 684687.
37. Lumetti, S, Ghiacci, G, Macaluso, GM, et al. Tardive dyskinesia, oral parafunction, and implant-supported rehabilitation. Case Rep Dent. 2016. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5168480/. Accessed August 11, 2017.
38. Portnoy, RA. Hyperkinetic dysarthria as an early indicator of impending tardive dyskinesia. J Speech Hear Disord. 1979; 44(2): 214219.
39. Myers, DE, Schooler, NR, Zullo, TG, Levin, H. A retrospective study of the effects of edentulism on the severity rating of tardive dyskinesia. J Prosthet Dent. 1993; 69(6): 578581.
40. Samie, MR, Dannenhoffer, MA, Rozek, S. Life-threatening tardive dyskinesia caused by metroclopramide. Mov Disord. 1987; 2(2): 125129.
41. Greenberg, DB, Murray, GB. Hyperventilation as a variant of tardive dyskinesia. J Clin Psychiatry. 1981; 42(10): 401403.
42. Chiang, E, Pitts, WM Jr, Rodriguez-Garcia, M. Respiratory dyskinesia: review and case reports. J Clin Psychiatry. 1985; 46(6): 232234.
43. Horiguchi, J, Shingu, T, Hayashi, T, et al. Antipsychotic-induced life-threatening “esophageal dyskinesia.”. Int Clin Psychopharm. 1999; 14(2): 123127.
44. Clark, GT, Ram, S. Orofacial movement disorders. Oral Maxillofac Surg Clin North Am. 2016; 28(3): 397407.
45. Caliguri, MP, Teulings, HL, Dean, CE, Lohr, JB. A quantitative measure of handwriting dysfluency for assessing tardive dyskinesia. J Clin Psychopharmacol. 2015; 35(2): 168174.
46. Neelam, K, Garg, D, Marshall, M. A systematic review and meta-analysis of neurological soft signs in relatives of people with schizophrenia. BMC Psychiatry.. 2011; 11: 139. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3173301/. Accessed August 11, 2017.
47. Burton, BK, Hjorthøj, C, Jepsen, JR, Thorup, A, Nordentoft, M, Plessen, KJ. Research review: do motor deficits during development represent an endophenotype for schizophrenia? A meta-analysis. J Child Psychol Psychiatry. 2016; 57(4): 446456.
48. Strassnig, M, Cornacchio, D, Harvey, PD, Kotov, R, Fochtmann, L, Bromet, EJ. Health status and mobility limitations are associated with residential and employment status in schizophrenia and bipolar disorder. J Psychiatr Res. 2017; 94: 180185.
49. Vrtunski, PB, Alphs, LD, Meltzer, HY. Isometric force control in schizophrenia patients with tardive dyskinesia. Psychiatry Res. 1991; 37(1): 5772.
50. Strassnig, M, Brar, JS, Ganguli, R. Low cardiorespiratory fitness and physical functional capacity in obese patients with schizophrenia. Schizophr Res. 2011; 126(1–3): 103109.
51. Waddington, JL, O’Callaghan, E, Larkin, C, Kinsella, A. Cognitive dysfunction in schizophrenia: organic vulnerability factor or state marker for tardive dyskinesia? Brain Cogn. 1993; 23(1): 5670.
52. Waddington, JL, Youssef, HA, Dolphin, C, Kinsella, A. Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia: their association in relation to topography of involuntary movements and criterion of their abnormality. Arch Gen Psychiatry. 1987; 44(10): 907912.
53. Waddington, JL, Youssef, HA, Kinsella, A. Cognitive dysfunction in schizophrenia followed up over 5 years, and its longitudinal relationship to the emergence of tardive dyskinesia. Psychol Med. 1990; 20(4): 835842.
54. Baribeau, J, Laurent, JP, Décary, A. Tardive dyskinesia and associated cognitive disorders: a convergent neuropsychological and neurophysiological approach. Brain Cogn. 1993; 23(1): 4055.
55. Spohn, HE, Coyne, L. The effect of attention/information processing impairment of tardive dyskinesia and neuroleptics in chronic schizophrenics. Brain Cogn. 1993; 23(1): 2839.
56. DeWolfe, AS, Ryan, JJ, Wolf, ME. Cognitive sequelae of tardive dyskinesia. J Nerv Ment Dis. 1988; 176(5): 270274.
57. Byne, W, White, L, Parella, M, Adams, R, Harvey, PD, Davis, KL. Tardive dyskinesia in a chronically institutionalized population of elderly schizophrenic patients: prevalence and association with cognitive impairment. Int J Geriatr Psychiatry. 1998; 13(7): 473479.
58. Pourcher, E, Cohen, H, Cohen, D, Baruch, P, Bouchard, RH. Organic brain dysfunction and cognitive deficits in young schizophrenic patients with tardive dyskinesia. Brain Cogn. 1993; 23(1): 8187.
59. Sachdev, P, Hume, F, Toohey, P, Doutney, C. Negative symptoms, cognitive dysfunction, tardive akathisia and tardive dyskinesia. Acta Psychiatr Scand. 1996; 93(6): 451459.
60. Struve, FA, Willner, AE. Cognitive dysfunction and tardive dyskinesia. Br J Psychiatry. 1983; 143: 597600.
61. Wegner, JT, Kane, JM, Weinhold, P, Woerner, M, Kinon, B, Lieberman, J. Cognitive impairment in tardive dyskinesia. Psychiatry Res. 1985; 16(4): 331337.
62. Wu, JQ, Chen, DC, Xiu, MH, et al. Tardive dyskinesia is associated with greater cognitive impairment in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 46: 7177.
63. Krabbendam, L, van Harten, PN, Picus, I, Jolles, J. Tardive dyskinesia is associated with impaired retrieval from long-term memory: the Curaçao Extrapyramidal Syndromes Study: IV. Schizophr Res. 2000; 42(1): 4146.
64. Miller, DD, McEvoy, JP, Davis, SM, et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res. 2005; 80(1): 3343.
65. Sarro, S, Pomarol-Clotet, E, Canales-Rodriguez, EJ, et al. Structural brain changes associated with tardive dyskinesia in schizophrenia. Br J Psychiatry. 2013; 203(1): 5157.
66. Pantelis, C, Stuart, GW, Nelson, HE, Robbins, TW, Barnes, TR. Spatial working memory deficits in schizophrenia: relationship with tardive dyskinesia and negative symptoms. Am J Psychiatry. 2001; 158(8): 12761285.
67. Emsley, R, Niehaus, DJ, Oosthuizen, PP, Koen, L, Chiliza, B, Fincham, D. Subjective awareness of tardive dyskinesia and insight in schizophrenia. Eur Psychiatry. 2011; 26(5): 293296.
68. Arango, C, Adami, H, Sherr, JD, Thaker, GK, Carpenter, WT Jr. Relationship of awareness of dyskinesia in schizophrenia to insight into mental illness. Am J Psychiatry. 1999; 156(7): 10971099.
69. Emsley, R, Niehaus, DJH, Oosthuizen, L, Koen, L, Chiliza, B, Fincham, D. Subjective awareness of tardive dyskinesia and insight in schizophrenia. Eur Psychiatry. 2011; 26(5): 293296.
70. Myslobodsky, MS, Tomer, R, Holden, T, Kempler, S, Sigal, M. Cognitive impairment in patients with tardive dyskinesia. J Nerv Ment Dis. 1985; 173(3): 156160.
71. Macpherson, R, Collis, R. Tardive dyskinesia. Patients’ lack of awareness of movement disorder. Br J Psychiatry. 1992; 160: 110112.
72. Gould, F, McGuire, LS, Durand, D, et al. Self-assessment in schizophrenia: accuracy of evaluation of cognition and everyday functioning. Neuropsychology. 2015; 29(5): 675682.
73. Meltzer, HY. Suicide in schizophrenia: risk factors and clozapine treatment. J Clin Psychiatry. 1998; 59(Suppl 3): 1520.
74. Hierholzer, RW. Tardive dyskinesia with complaints of pain. Am J Psychiatry. 1989; 146(6): 802.
75. Earle, J Jr, Patterson, WM. Chronic pain, neuroleptics, and tardive dyskinesia. Psychosomatics. 1986; 27(4): 291293.
76. Blanchet, PJ, Popovici, R, Guitard, F, Rompré, PH, Lamarche, C, Lavigne, GJ. Pain and denture condition in edentulous orodyskinesia: comparisons with tardive dyskinesia and control subjects. Mov Disord. 2008; 23(13): 18371842.
77. Schoonderwoerd, K. Chiropractic management of musculoskeletal pain secondary to tardive dyskinesia. J Can Chiropr Assoc. 2005; 49(2): 9295.
78. Jeste, DV, Caliguri, MP. Tardive dyskinesia. Schizophr Bull. 1993; 19(2): 303315.
79. Strassnig, M, Signorile, J, Gonzalez, C, Harvey, PD. Physical performance and disability in schizophrenia. Schizophr Res Cogn. 2014; 1(2): 112121.
80. Yassa, R. Functional impairment in tardive dyskinesia: medical and psychosocial dimensions. Acta Psychiatr Scand. 1989; 80(1): 6467.
81. Dean, CE, Russell, JM, Kuskowski, MA, Caligiuri, MP, Nugent, SM. Clinical rating scales and instruments: how do they compare in assessing abnormal, involuntary movements? J Clin Psychopharmacol. 2004; 24(3): 298304.

Keywords

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed